Mannatech (MTEX) Competitors $8.57 +0.17 (+2.02%) Closing price 03:55 PM EasternExtended Trading$8.54 -0.04 (-0.41%) As of 05:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MTEX vs. ATYR, CNTB, ABVC, VNRX, ARTV, ANL, RLMD, HYPD, GANX, and NRXPShould you be buying Mannatech stock or one of its competitors? The main competitors of Mannatech include aTyr Pharma (ATYR), Connect Biopharma (CNTB), ABVC BioPharma (ABVC), VolitionRx (VNRX), Artiva Biotherapeutics (ARTV), Adlai Nortye (ANL), Relmada Therapeutics (RLMD), Hyperion DeFi (HYPD), Gain Therapeutics (GANX), and NRx Pharmaceuticals (NRXP). These companies are all part of the "pharmaceutical products" industry. Mannatech vs. Its Competitors aTyr Pharma Connect Biopharma ABVC BioPharma VolitionRx Artiva Biotherapeutics Adlai Nortye Relmada Therapeutics Hyperion DeFi Gain Therapeutics NRx Pharmaceuticals Mannatech (NASDAQ:MTEX) and aTyr Pharma (NASDAQ:ATYR) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, media sentiment, valuation and earnings. Does the media prefer MTEX or ATYR? In the previous week, aTyr Pharma had 11 more articles in the media than Mannatech. MarketBeat recorded 13 mentions for aTyr Pharma and 2 mentions for Mannatech. Mannatech's average media sentiment score of 0.95 beat aTyr Pharma's score of 0.25 indicating that Mannatech is being referred to more favorably in the media. Company Overall Sentiment Mannatech Positive aTyr Pharma Neutral Which has preferable valuation & earnings, MTEX or ATYR? Mannatech has higher revenue and earnings than aTyr Pharma. Mannatech is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMannatech$117.87M0.14$2.49M-$2.04-4.20aTyr Pharma$230K406.02-$64.02M-$0.80-1.19 Which has more risk & volatility, MTEX or ATYR? Mannatech has a beta of 0.81, indicating that its share price is 19% less volatile than the S&P 500. Comparatively, aTyr Pharma has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500. Is MTEX or ATYR more profitable? aTyr Pharma has a net margin of 0.00% compared to Mannatech's net margin of -3.46%. Mannatech's return on equity of -48.60% beat aTyr Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Mannatech-3.46% -48.60% -10.70% aTyr Pharma N/A -93.69%-68.83% Do analysts prefer MTEX or ATYR? aTyr Pharma has a consensus price target of $23.25, suggesting a potential upside of 2,339.66%. Given aTyr Pharma's stronger consensus rating and higher possible upside, analysts clearly believe aTyr Pharma is more favorable than Mannatech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mannatech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00aTyr Pharma 1 Sell rating(s) 6 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Do insiders & institutionals hold more shares of MTEX or ATYR? 13.0% of Mannatech shares are owned by institutional investors. Comparatively, 61.7% of aTyr Pharma shares are owned by institutional investors. 41.5% of Mannatech shares are owned by insiders. Comparatively, 3.7% of aTyr Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. SummaryaTyr Pharma beats Mannatech on 9 of the 16 factors compared between the two stocks. Get Mannatech News Delivered to You Automatically Sign up to receive the latest news and ratings for MTEX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MTEX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MTEX vs. The Competition Export to ExcelMetricMannatechMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$15.97M$2.65B$6.14B$10.66BDividend YieldN/A57.76%5.72%4.71%P/E Ratio-4.2023.7585.8427.65Price / Sales0.14790.12626.13140.50Price / Cash3.93177.3038.3262.20Price / Book1.885.6413.066.79Net Income$2.49M$32.78M$3.30B$275.88M7 Day Performance-2.06%6.31%4.81%2.64%1 Month Performance-5.98%13.80%9.99%9.13%1 Year Performance10.44%2.75%85.28%35.89% Mannatech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MTEXMannatech1.143 of 5 stars$8.57+2.0%N/A+12.0%$15.97M$117.87M-4.20250Analyst ForecastGap UpATYRaTyr Pharma3.1964 of 5 stars$0.73-8.2%$23.25+3,084.9%-48.5%$71.53M$230K-0.9153Analyst ForecastInsider TradeHigh Trading VolumeCNTBConnect Biopharma3.552 of 5 stars$1.28-2.8%$7.00+446.9%+42.2%$71.32M$26.03M0.00110Analyst ForecastABVCABVC BioPharma0.8915 of 5 stars$3.02-2.1%N/A+467.4%$70.97M$510K-17.7330News CoverageAnalyst ForecastVNRXVolitionRx2.2197 of 5 stars$0.66+5.3%$3.50+433.5%-16.1%$70.58M$1.32M-1.8280News CoverageGap DownHigh Trading VolumeARTVArtiva Biotherapeutics3.3413 of 5 stars$2.85-2.4%$17.00+496.7%-79.8%$69.60M$250K0.0081News CoveragePositive NewsAnalyst ForecastANLAdlai Nortye1.8656 of 5 stars$1.80+1.7%$9.00+400.0%-10.7%$66.42M$5M0.00127News CoveragePositive NewsAnalyst ForecastAnalyst RevisionRLMDRelmada Therapeutics2.7617 of 5 stars$1.99+5.6%$1.00-49.6%-39.0%$65.88MN/A-0.8910Analyst ForecastGap DownHYPDHyperion DeFi0.6861 of 5 stars$9.31-9.1%$2.00-78.5%-74.9%$64.80M$60K-0.1640Analyst ForecastGANXGain Therapeutics3.0117 of 5 stars$1.78-1.7%$8.00+349.4%+4.5%$63.99M$50K-2.8320News CoveragePositive NewsAnalyst ForecastOptions VolumeHigh Trading VolumeNRXPNRx Pharmaceuticals3.1954 of 5 stars$3.22-0.9%$34.50+971.4%+141.9%$63.69MN/A-1.442Analyst Forecast Related Companies and Tools Related Companies ATYR Alternatives CNTB Alternatives ABVC Alternatives VNRX Alternatives ARTV Alternatives ANL Alternatives RLMD Alternatives HYPD Alternatives GANX Alternatives NRXP Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MTEX) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mannatech, Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Mannatech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
